Related references
Note: Only part of the references are listed.Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness - Poor prognosis in patients with pancreatic ductal adenocarcinoma
S Ueda et al.
PANCREAS (2004)
Mechanisms of resistance to erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells
JP Arnoletti et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2004)